Quis custodiet ipsos custodies: who watches the watchmen? Witkiewicz, Dasgupta, and colleagues independently investigated the clinical significance of stromal Cav-1 expression in a breast tumor tissue microarray. The presence of stromal Cav-1 was strongly associated with tumor size, local spread to lymph nodes, and progression-free survival in Tamoxifen-treated and -untreated patients. Again, tumor Cav-1 expression did not correlate with either of the described metrics 11 . Strikingly, both studies found that stromal Cav-1 expression predicted patient survival independent of estrogen receptor (ER), progesterone receptor (PR), or HER2 status 10, 11 . Results from these two clinical studies suggest that stromal Cav-1 expression may be a new independent prognostic factor for long-term survival and disease recurrence for breast cancer patients, and the Tamoxifen data suggest that expression of this stromal marker may also predict resistance to treatment.
Should this be said again? No cell is an island and in tissue-specificity and cancer, context is supreme.
Decades ago, seminal recombination experiments illustrated the dominant role of mammary mesenchyme in directing epithelial development [1] [2] [3] , and strongly suggested that the microenvironment plays a significant role also in the manifestation of carcinoma. More direct evidence for such functions came from a study demonstrating that an unadulterated microenvironment can suppress the malignant phenotype and re-direct tumor cells to give rise to normally functioning tissues and indeed healthy mice 4 . One may wonder why such a stunning finding did not convince the scientific community to pay more attention to the role of context.
The answers are complex, not the least of which is that concomitantly with this finding, the roles of oncogenes and mutations were being discovered. That excitement carried the day, specially because no one subsequently determined whether or not these mice generated from malignant cells contained tumorigenic mutations, and no new group reproduced the work. The following decade saw the discovery that even potent oncogenes could be ruled by context 5 , and another couple of decades later it was shown that similar reprogramming of metastatic melanoma by an embryonic microenvironment was possible 6 . There are many more examples which are not as clear cut, but are nevertheless compelling. The extensive literature of two-stage carcinogenesis, namely initiation and progression, indeed clearly indicates that "initiation" and DNA damage alone are not sufficient to allow carcinogenesis.
Implicit in these findings is: once a tumor or an oncogene, not always a tumor or an oncogene. A renewed focus on the tumor microenvironment as a therapeutic target 7 has also led to the recognition that markers within the microenvironment could have predictive power. Two recently published reports identifying 'stromal signatures' in breast cancer patients prognostic for patient survival 8 10, 11 . Results from these two clinical studies suggest that stromal Cav-1 expression may be a new independent prognostic factor for long-term survival and disease recurrence for breast cancer patients, and the Tamoxifen data suggest that expression of this stromal marker may also predict resistance to treatment.
As with any exciting study, intriguing data raise a number of questions which sow the soil for future studies. Principle amongst these questions is whether Cav-1 is a surrogate or a functional biomarker (summarized in Figure 2 ):
An argument for Cav-1 being a functional biomarker is that its absence may reflect the physical absence of a Cav-1-expressing cell type (Fig. 2, Scenario 1 If not a surrogate biomarker, Cav-1 may instead be a functional biomarker directly responsible for the tumor suppressor functions of MEPs (Fig. 2, Scenario 2) . Carcinoma- shown that loss of Cav-1 induces a carcinoma-associated fibroblast (CAF) phenotype 23 , which actively participates in tumor progression 24, 25 . Loss of Cav-1 expression may directly mediate transition to the CAF phenotype and promote tumor growth by either attenuating the activity of a tumor suppressor (e.g., retinoblastoma tumor suppressor 23 ), activating TGF-β expression, and/or modulating TGF-β receptor activity 26, 27 .
Regardless of which scenario may be operating, it is of interest that neither study positively correlated stromal Cav-1 expression with distant metastases (i.e., M-stage). Further.
the offspring of Cav-1 null mice and Her-2/neu mice (which develop mammary-specific tumors)
established by Sloan et al. 10 developed tumors faster and required more rapid sacrificing than
Her-2/neu counterparts, but did not show increased lung metastases. In light of the survival data, however, the simple question remains: why do patients lacking stromal Cav-1 expression die so fast? It is well accepted that metastatic growths are the cause of breast cancer-related deaths, so determining whether lack of stromal Cav-1 expression at the primary site mediates escape from tumor dormancy at the secondary site in already established mouse models 14 may yield intriguing results. Elaborating upon such studies by deleting Cav-1 in specific cell types (e.g., MEPs, adipocytes) could reveal whether Cav-1 expression is crucial only within certain cell populations and also pinpoint which cell type(s) to use for interrogation of the molecular mechanisms by which reduced Cav-1 expression enhances tumor growth and invasion.
Given the striking prognostic finding of Cav-1 loss in the tumor microenvironment, a final point of discussion is whether stromal Cav-1 also provides a meaningful therapeutic target. 
